Autogenomics Prescient Medicine, Erasmus MC Partner to Study Opioid Addiction Risk Test Prescient offers a test that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway. Prescient Medicine Acquires AutoGenomics Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder. FDA Grants Breakthrough Designation for AutoGenomics' Infiniti Neural Response Panel The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance. Prescient Medicine Launches Addiction Risk Test Developed With AutoGenomics Premium The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications. WuXi to Distribute AutoGenomics' MDx System in China The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients. Jul 24, 2015 AutoGenomics to Withdraw Planned IPO; Eyes Launch of New MDx Platform in Q1 2016 Premium Feb 4, 2015 AutoGenomics Sets Price Range for Planned IPO, Anticipates up to $46.6M in Proceeds Oct 8, 2014 AutoGenomics Seeks to Raise $60M in IPO Jul 9, 2014 Genomas, Autogenomics Codeveloping Multiplex Genetic Test for Statin Efficacy and Adverse Events Premium Jul 7, 2014 Genomas, AutoGenomics Partner to Advance Dx to Personalize Statin Treatments Apr 8, 2014 IP Watch: Epigenomics, Fluidigm, Sony, Life Tech, Others Win US Patents Premium Nov 4, 2013 MDx Firm AutoGenomics Withdraws IPO Sep 4, 2013 Spartan to Continue Talks with FDA as it Aims for Point-of-Care Indication for CYP2C19 Test Premium Aug 29, 2013 FDA Clearance of Spartan Assay Inches CYP2C19 Genotyping Closer to Point of Care Premium Feb 25, 2013 Most Viewed Articles on GWDN Last Week: Feb 25, 2013 Feb 18, 2013 AutoGenomics Withdraws IPO for Second Time Jan 23, 2013 AutoGenomics Lowers Proceeds Expected from IPO Nov 2, 2012 AutoGenomics Reports Sharp Rise in Revenues for First Nine Months of 2012 Sep 27, 2012 AutoGenomics Targets $65M IPO Jun 27, 2012 AutoGenomics Gets Health Canada OK for PGx System Mar 28, 2012 FDA Disputes Claims that it Prematurely Updated Plavix Label with PGx Information Premium Mar 14, 2012 Does Lack of PGx Link in Recent Studies Foreshadow End of CYP2D6 Genotyping for Tamoxifen? Premium Feb 15, 2012 Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests Premium Jun 22, 2011 'Not Approvable' Letter Thwarts Nanosphere's Hopes to Launch FDA-Approved Plavix PGx Test Premium May 19, 2011 AutoGenomics Withdraws IPO Load More Breaking News People in the News at Probius, Flagship Biosciences, Discovery Life Sciences, More New Products Posted to GenomeWeb: BillionToOne, Becton Dickinson, Enzo Biochem, More Stroke Risk Contributors, Treatment Targets Uncovered in Cross-Ancestry GWAS In Brief This Week: Yourgene Health, Bionano Laboratories, Caris Life Sciences, More Enzymatic RNA Synthesis Firm EnPlusOne Biosciences Launches With $12M in Seed Funding The Scan Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says. Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds. Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry. UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.